DE3686361T3 - Verwendung von Bismuth zur Herstellung von Medikamenten zur Behandlung von Magen-Darmstörungen, die von Campylobacter polyridis verursacht sind. - Google Patents

Verwendung von Bismuth zur Herstellung von Medikamenten zur Behandlung von Magen-Darmstörungen, die von Campylobacter polyridis verursacht sind.

Info

Publication number
DE3686361T3
DE3686361T3 DE3686361T DE3686361T DE3686361T3 DE 3686361 T3 DE3686361 T3 DE 3686361T3 DE 3686361 T DE3686361 T DE 3686361T DE 3686361 T DE3686361 T DE 3686361T DE 3686361 T3 DE3686361 T3 DE 3686361T3
Authority
DE
Germany
Prior art keywords
campylobacter
bismuth
treatment
polyridis
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3686361T
Other languages
English (en)
Other versions
DE3686361T2 (de
DE3686361D1 (de
Inventor
Barry James Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24994180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3686361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3686361D1 publication Critical patent/DE3686361D1/de
Publication of DE3686361T2 publication Critical patent/DE3686361T2/de
Publication of DE3686361T3 publication Critical patent/DE3686361T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE3686361T 1985-06-13 1986-06-10 Verwendung von Bismuth zur Herstellung von Medikamenten zur Behandlung von Magen-Darmstörungen, die von Campylobacter polyridis verursacht sind. Expired - Lifetime DE3686361T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74484285A 1985-06-13 1985-06-13

Publications (3)

Publication Number Publication Date
DE3686361D1 DE3686361D1 (de) 1992-09-17
DE3686361T2 DE3686361T2 (de) 1993-02-11
DE3686361T3 true DE3686361T3 (de) 2003-01-09

Family

ID=24994180

Family Applications (4)

Application Number Title Priority Date Filing Date
DE8686304409T Expired - Lifetime DE3686362T2 (de) 1985-06-13 1986-06-10 Verfahren zur behandlung von magen-darmstoerungen.
DE3686361T Expired - Lifetime DE3686361T3 (de) 1985-06-13 1986-06-10 Verwendung von Bismuth zur Herstellung von Medikamenten zur Behandlung von Magen-Darmstörungen, die von Campylobacter polyridis verursacht sind.
DE19863619733 Withdrawn DE3619733A1 (de) 1985-06-13 1986-06-12 Mittel zur behandlung von magen-darm-stoerungen
DE19863619734 Withdrawn DE3619734A1 (de) 1985-06-13 1986-06-12 Mittel zur behandlung von magen-darm-stoerungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE8686304409T Expired - Lifetime DE3686362T2 (de) 1985-06-13 1986-06-10 Verfahren zur behandlung von magen-darmstoerungen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE19863619733 Withdrawn DE3619733A1 (de) 1985-06-13 1986-06-12 Mittel zur behandlung von magen-darm-stoerungen
DE19863619734 Withdrawn DE3619734A1 (de) 1985-06-13 1986-06-12 Mittel zur behandlung von magen-darm-stoerungen

Country Status (8)

Country Link
US (1) US5601848A (de)
EP (2) EP0206626B2 (de)
JP (1) JPH0794391B2 (de)
AT (2) ATE79261T1 (de)
BE (1) BE904922A (de)
DE (4) DE3686362T2 (de)
IE (2) IE59585B1 (de)
PH (1) PH26891A (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG72632A1 (en) * 1985-04-18 2000-05-23 Procter & Gamble Treatment of non-ulcer dyspepsia with bismuth salts
EP0282132B1 (de) * 1987-03-09 1992-09-30 The Procter & Gamble Company Zusammensetzungen und ihre Verwendung zur Behandlung von Magen-Darmstörungen
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
US5196205A (en) * 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders
AU609999B2 (en) * 1988-06-21 1991-05-09 Marion Laboratories, Inc. Bismuth (phosph/sulf)ated saccharides
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
ES2040307T3 (es) * 1988-10-08 1993-10-16 Dr. R. Pfleger Chemische Fabrik Gmbh Procedimiento para producir un preparado medicamentoso liquido que contiene bismuto.
DE3901508C2 (de) * 1989-01-19 1994-04-07 Falk Pharma Gmbh Arzneimittel auf der Grundlage eines Wismut enthaltenden Präparats in fester Form
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
DE4294862T1 (de) * 1992-04-10 1994-06-09 Vni Skij I Medicinskich Polime Pharmazeutische Komposition
US5376553A (en) * 1993-06-18 1994-12-27 University Of Florida Clinical marker and therapeutic agent in kidney stone disease and methods of use
WO1995008332A1 (en) * 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
WO1995012579A1 (en) * 1993-11-05 1995-05-11 Otsuka Pharmaceutical Company, Limited Bismuth salt of carbostyril derivatives for the treatment of peptic ulcers
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5607964A (en) * 1994-06-17 1997-03-04 University Of Florida Clinical marker and therapeutic agent in kidney stone disease and methods of use
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5702729A (en) * 1995-12-07 1997-12-30 The Procter & Gamble Company Methods for the prevention and treatment of gastrointestinal disorders caused or mediated by algae or cyanobacteria
DE69618617T2 (de) * 1995-12-07 2002-09-19 Procter & Gamble Wismuth enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
GB9623962D0 (en) * 1996-11-15 1997-01-08 Tillotts Pharma Ag Pharmaceutical composition
US6186958B1 (en) 1997-02-26 2001-02-13 Oridion Medical Breath test analyzer
MX9703918A (es) 1997-05-28 1998-11-30 J Marshall M D Barry Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior.
USRE38728E1 (en) * 1997-09-11 2005-04-19 Oridion Medical, LTD Breath test analyzer
US6929926B2 (en) 2001-10-15 2005-08-16 Barry J. Marshall Composition for the detection of gastrointestinal disorders
US20030072686A1 (en) * 2001-10-15 2003-04-17 Marshall Barry J. Systems for performing multiple diagnostic tests
US6998250B2 (en) 2001-10-15 2006-02-14 Donald J. McMichael Method for detecting Helicobacter pylori
US20030073155A1 (en) * 2001-10-15 2003-04-17 Mcmichael Donald J. Methods for performing multiple diagnostic tests
US7008777B2 (en) * 2001-10-15 2006-03-07 Barry J. Marshall System for the detection of urease and method for using same
USD484988S1 (en) 2001-12-17 2004-01-06 Kimberly-Clark Worldwide, Inc. Diagnostic test kit with specimen-handling tool
US6783976B2 (en) 2001-12-21 2004-08-31 Kimberly-Clark Worldwide, Inc. Carrier and specimen-handling tool for use in diagnostic testing
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
WO2007090113A2 (en) 2006-02-01 2007-08-09 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
FR2913403B1 (fr) 2007-03-05 2009-05-29 Astrium Sas Soc Par Actions Si Commande d'actionneur reduisant le niveau de vibrations d'une structure flexible associee
CA2858090A1 (en) * 2011-12-20 2013-06-27 Gilead Sciences, Inc. Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301743A (de) * 1962-12-13
FR4961M (de) * 1965-03-29 1967-04-03
FR5877M (de) * 1966-07-22 1968-03-18
FR6197M (de) * 1967-04-12 1968-07-22
US3577533A (en) * 1968-02-21 1971-05-04 Joseph Alfred Rider Antacid compositions containing bismuth aluminate and coprecipitated aluminum hydroxide and magnesium carbonate
US4153685A (en) * 1968-11-23 1979-05-08 Schering Corporation Bismuth complex preparations
FR2053002A1 (en) 1969-06-21 1971-04-16 Clin Midy Bismuth slats of alpha methiminobenzyl - penicillin
DE1963496A1 (de) * 1969-12-18 1971-06-24 Hans Voigt Chemisch Pharmazeut Pharmazeutisches Praeparat zur Behandlung von Magen-Darm-Erkrankungen
US4118480A (en) * 1973-02-09 1978-10-03 Charles V. Stoelker Pharmaceutical preparation for treating hemorrhoids and anal fissures
ZA74385B (en) * 1974-01-18 1975-08-27 Gist Brocades Nv Pharmaceutical compositions
US4016268A (en) * 1975-10-06 1977-04-05 Morton-Norwich Products, Inc. Method of combatting gastric ulceration
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
PH20649A (en) * 1981-09-22 1987-03-16 Gist Brocades Nv Bismuth containing composition and method for the preparation thereof
US4588589A (en) * 1983-10-13 1986-05-13 Richardson-Vicks Inc. Antidiarrheal compositions and use thereof

Also Published As

Publication number Publication date
JPS6248624A (ja) 1987-03-03
EP0206627A3 (en) 1989-04-05
IE861573L (en) 1986-12-13
EP0206626A2 (de) 1986-12-30
JPH0794391B2 (ja) 1995-10-11
EP0206626A3 (en) 1989-04-12
DE3619734A1 (de) 1987-02-12
IE59585B1 (en) 1994-03-09
IE861574L (en) 1986-12-13
PH26891A (en) 1992-11-03
ATE79264T1 (de) 1992-08-15
ATE79261T1 (de) 1992-08-15
DE3686361T2 (de) 1993-02-11
EP0206627A2 (de) 1986-12-30
IE59584B1 (en) 1994-03-09
DE3686361D1 (de) 1992-09-17
DE3686362D1 (de) 1992-09-17
EP0206626B2 (de) 2002-05-22
BE904922A (fr) 1986-12-15
DE3619733A1 (de) 1987-02-12
EP0206627B1 (de) 1992-08-12
DE3686362T2 (de) 1993-02-11
EP0206626B1 (de) 1992-08-12
US5601848A (en) 1997-02-11

Similar Documents

Publication Publication Date Title
DE3686361T3 (de) Verwendung von Bismuth zur Herstellung von Medikamenten zur Behandlung von Magen-Darmstörungen, die von Campylobacter polyridis verursacht sind.
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE68910175T3 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE3855527T2 (de) Doppelsträngige RNS zur Korrektur von Abnormalitäten von zirkulierenden Immunkomplexen und der Monozytenfunktion
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
ATE196738T1 (de) Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
ATE216266T1 (de) Einen liganden enthaltendes arzneimittel zur behandlung und/oder diagnose von weichgeweben- tumoren
DE59206036D1 (de) Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
DE3675115D1 (de) Verwendung von verbindungen zur herstellung eines medikaments fuer die behandlung von grauem star.
LU81578A1 (de) 1,2,3-triazolcarbonsaeureamide,verfahren zur herstellung dieser verbindungen sowie diese enthaltende biozide mittel
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
FI901371A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten halogeeni-3,4-dihydro-bentsotiopyranyyliamiinien valmistamiseksi
DE3674213D1 (de) Verfahren zur herstellung von keimabgetoeteten oder in ihrer virulenz abgeschwaechten substanzen sowie deren verwendung.
DE3578374D1 (de) Verwendung von chinolonen fuer die herstellung eines arzneimittels zur behandlung von herzerkrankungen.
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE128188T1 (de) Menschliches gamma-interferon, verfahren zu seiner herstellung und seine verwendung.
PT65900A (de) 5-alkylureido-1,3,4-thiadiazol-2-yl-sulfonyl-essigsaeure-derivate,verfahren zur herstellung diesel verbindungen sowie diese enthaltende herbizide mittel
DE3679780D1 (de) Substituierte aminosulfonyl-6-nitrobenzosaeureester oder -amide, verfahren zur herstellung und diese enthaltende heilmittel.
DE69427927T2 (de) Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind.
PT66822A (de) 1,3,3-trimethyl-6-azabicyclo-(3,2,1)-octan-6-carbonsaeureester,verfahren zur herstellung dieser verbindungen sowie diese enthaltende herbizide mittel
ATE57678T1 (de) Verwendung von verbindungen zur herstellung eines medikaments fuer die behandlung von grauem star.

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER PATENTINHABER LAUTET RICHTIG: MARSHALL, BARRY JAMES, DR., EARLYSVILLE, VA., US

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings